Intervention Protocol

Alemtuzumab for chronic lymphocytic leukaemia

  1. Thomas Elter1,*,
  2. Olaf Weingart2,
  3. Kathrin Bauer2,
  4. Corinne Brillant2,
  5. Christine Herbst2,
  6. Ina Monsef2,
  7. Nicole Skoetz2,
  8. Andreas Engert2

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 30 MAR 2009

DOI: 10.1002/14651858.CD008078

Database Title

Additional Information

How to Cite

Elter T, Weingart O, Bauer K, Brillant C, Herbst C, Monsef I, Skoetz N, Engert A. Alemtuzumab for chronic lymphocytic leukaemia (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD008078. DOI: 10.1002/14651858.CD008078.

Author Information

  1. 1

    University Hospital of Cologne, Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, Cologne, Germany

  2. 2

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

*Thomas Elter, Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. thomas.elter@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 7 OCT 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (144K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The objective of this review is to asses and summarise the evidence for treatment of CLL patients with alemtuzumab.

View Full Article (HTML) Full (144K)